Serina Therapeutics (SER) Investor presentation summary

Platform overview and strategy

• POZ platform enables next-generation drug product optimization for multiple modalities, including CNS small molecules, immune-silent delivery, and novel ADC payloads.

• Focus on re-engineering clinically validated molecules to improve pharmacokinetics, tolerability, and dosing burden.

• Platform supports repeatability, with a pipeline of CNS-focused assets beyond the lead candidate.

Lead asset and clinical development

• SER-252, a POZ-apomorphine conjugate, targets advanced Parkinson's disease with a Phase 1b registrational study underway.

• Designed for continuous dopaminergic stimulation without surgery or daily pump setup, using a compact, patient-centered on-body device.

• First patient dosed in February 2026; Cohort 1 dosing completed July 2026; topline SAD data expected 1H 2027.

• Study aims to address safety, tolerability, pharmacokinetics, and usability in the target population.

Market opportunity and differentiation

• Advanced Parkinson's disease represents a large, underpenetrated market, with ~250,000 patients inadequately controlled on oral therapy in US/EU4+UK.

• Existing continuous therapies validate demand but have limitations in administration burden and site reactions.

• SER-252 aims to offer a best-in-class profile with 2x weekly, brief on-body delivery and no visible needle or tubing.

• Peak annual sales opportunity estimated at $1.8B base case, with upside to $2.7B if market expands.